CINCINNATI, July 12, 2016 /PRNewswire/ -- Schulman IRB, the industry-leading central IRB in customer service and technology, announced today that Michele Russell-Einhorn, JD, will join the organization September 1, 2016, as Vice President for Oncology Services.
In her new role, Ms. Russell-Einhorn will build and lead Schulman's forthcoming Central Oncology Review (COR) division, launching later in 2016. COR represents Schulman's response to many requests from institutional research centers looking for a more advanced level of partnership and service integration.
"Ms. Russell-Einhorn understands the unique needs of large comprehensive cancer centers, and she is intimately familiar with the operational requirements of institutional research offices," said Michael Woods, President and CEO of Schulman IRB. "Her expertise and leadership will help ensure COR offers review services of the highest quality."
As Senior Director of Dana-Farber Cancer Institute's Office for Human Research Studies, an office that reviews cancer research on behalf of the five Harvard institutions comprising the Dana-Farber/Harvard Cancer Center, Ms. Russell-Einhorn managed and oversaw five scientific review committees and seven institutional review boards (IRBs). She also coordinated with the institutional offices of hospitals participating in the Dana-Farber/Harvard Cancer Center.
Ms. Russell-Einhorn currently serves as Co-Chair of the Subpart A Subcommittee of the US Department of Health and Human Services (DHHS) Secretary's Advisory Committee on Human Research Protections. She is also a founding member and leader of the IRB Directors group for the National Comprehensive Cancer Network (NCCN) and is a site visitor for the Association for the Accreditation of Human Research Protection Programs (AAHRPP). Prior to joining Dana-Farber, Ms. Russell-Einhorn served as the Assistant Special Counsel for Ethics for NIH, the Director of Regulatory Affairs for the Office for Protection from Research Risks and the Office for Human Research Protections, as well as the Associate General Counsel for the J Craig Ventor Institute.
About Schulman IRB Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its Provision Research Compliance Services division, offering comprehensive solutions to maximize the protection of human subjects and improve overall quality standards for clinical studies and data integrity. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).